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Objectives This study sought to identify proteins from the cardiomyocyte (CM) secretome that are directly targeted by the
muscle-specific microRNA-1 (miR-1), and thus reflect the pathophysiological state of the CM.
Background MicroRNAs play critical regulatory roles during myocardial remodeling and progression to heart failure. However,
it remains unknown whether secreted microRNA-targeted proteins can be used as indicators of myocardial
microRNA expression and function.
Methods A proteomic analysis based on multidimensional protein identification technology was performed on superna-
tants from cultured CMs overexpressing miR-1. Biochemical assays and an inducible cardiac-specific transgenic
mouse model overexpressing miR-1 were used to demonstrate that heart-type fatty acid-binding protein-3
(FABP3) is a target of miR-1. Levels of miR-1 and FABP3 in cardiac tissue and plasma samples from mouse
models as well as human patients were quantified by quantitative reverse-transcription polymerase chain reac-
tion and enzyme-linked immunosorbent assay, respectively. The study included wild-type mice subjected to ven-
tricular pressure overload or fasting, as well as patients diagnosed with ventricular hypertrophy due to valvular
aortic stenosis, acromegaly, or growth hormone deficiency, conditions associated with altered miR-1 expression.
Results An inverse relationship between myocardial expression of miR-1 and circulating levels of FABP3 was found both
in vitro and in vivo under various pathological conditions.
Conclusions Assessment of FABP3 plasma levels in human patients might be used for indirectly measuring cardiac miR-1
activity. (J Am Coll Cardiol 2013;61:88–95) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1003Cardiomyocytes (CMs) produce a wide variety of bioactive
molecules that regulate myocardial processes such as hyper-
trophic growth, excitation–contraction coupling as well as
structural and metabolic remodeling. The proteins that are
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Manuscript received July 2, 2012; accepted August 31, 2012.actively released into the interstitial space or the blood-
stream are known to be important for homeostasis, not only
of the heart, but also of the whole organism (1). Release may
take place in response to either physiological stimuli or
pathological stresses, and failure to adequately adjust to
these changing conditions may lead to cardiac dysfunction.
Many of the compensatory mechanisms associated with
physiological or pathological processes in the heart may be
related to alterations in the expression profile of specific
microRNAs (miRs) (2). MiRs are small noncoding RNAs
that negatively modulate the translation of target mRNAs
by recognizing specific binding sites in the 3= untranslated
regions (UTRs) (2). In the heart, the striated muscle–
specific miR-1 has been highlighted for its critical role in
orchestrating myocardial development and function as well
as structural remodeling associated with the progression of
heart failure (HF). In a recent work, we demonstrated a
feedback loop in which miR-1 and the insulin-like growth
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ular, we showed that IGF-1 as well its receptor are targets of
miR-1, whose expression per se depends on, as recently
supported (4), the activation state of the IGF-1 signal trans-
duction cascade. This mechanism likely plays an important role
in the modulation of cardiac and skeletal muscle development
and hypertrophy. On the basis of this and increasing evidence
demonstrating an important role of miR-1 in regulating
cardiac function and disease, we hypothesized that miR-1 may
also be involved in modulating the levels of proteins secreted by
CMs (i.e., the CM secretome). Identifying miR targets that
are actively secreted by a specific cell type might be useful for
identifying indirect circulating biomarkers that indicate the
pathophysiological state of the cell by reflecting the cellular
levels of the targeting miR.
Here, we demonstrate that miR-1 regulates the level of
fatty acid-binding protein-3 (FABP3), a small cytoplasmic
protein involved in cardiac metabolism and released into the
bloodstream by CMs following ischemic episodes (5), and
we identify circulating FABP3 as an indirect biomarker for
miR-1 myocardial expression.
Methods
See the Methods section of the Online Appendix.
Results
FABP3 is a direct target of miR-1. CMs are known to
secrete a variety of bioactive molecules involved in a plethora
of autocrine/paracrine mechanisms. We therefore asked
whether alterations in miR expression levels, in particular
those related to the muscle-specific miR-1, might be in-
volved in the modulation of the CM secretome. To this end,
a proteomic analysis based on multidimensional protein
identification technology (6) was performed on supernatants
from in vitro neonatal CMs infected with either a miR-1–
expressing adenoviral vector (AdmiR1) or empty vector
(Adempty). Among the proteins that were differentially
down-regulated in the AdmiR1-treated samples (Online
Fig. 1) was FABP3. Due to the considerable interest in
the identification of novel biomarkers for early detection
of the molecular events underlying cardiac progression to
HF, we focused our attention on FABP3, the secretion of
which is associated with ischemic conditions (7). Findings
of other differentially expressed proteins from the proteom-
ics analysis will be published elsewhere.
MiR–mRNA interaction is initiated by base pairing of
the miR’s seed sequence, found at the 5= end, to a binding
site present on the 3=-UTR of the targeted mRNA. How-
ever, with web-based bioinformatics algorithms, we could
not find any canonical binding site for the 5= seed sequence
of miR-1 on the 3=-UTR of FABP3 mRNA. Because
growing evidence indicates that base pairing outside of the
seed sequence can compensate for imperfect seed matching
(8), we assessed whether FABP3 mRNA might represent a
noncanonical miR-1 target (Fig. 1A). To this end, a dual-luciferase assay was performed on
293 cells that do not endogenously
express miR-1. Briefly, either wild-
type or mutant FABP3 3=-UTR
cloned downstream of a luciferase
reporter gene was transfected into
293 cells before transduction with
either AdmiR1 or Adempty. In cul-
tures exposed to AdmiR1, we found
a significant decrease in luciferase
activity with the construct contain-
ing wild-type FABP3 3=-UTR,
whereas no effect was found with the
construct containing a 3=-UTR mu-
tated in the putative miR-1 binding
site (Fig. 1B). Similar results were
obtained using a synthetic miR-1
mimic and scramble oligos in
the place of the adenoviral vec-
tors (Online Fig. 2).
To further confirm that miR-1
binds to the FABP3 3=-UTR,
immunoprecipitation of biotinyl-
ated miR-1 oligo was performed
on homogenate from adult
mouse heart followed by RNA
extraction and PCR analysis for
FABP3 mRNA. Consistent with
the preceding results, a specific
PCR signal for FABP3 was ob-
tained, which was absent in the
negative control (Fig. 1C). In addition, Western blot
analysis of 293 cells transduced with AdmiR1 revealed a
decrease in FABP3 protein levels upon miR-1 overexpres-
sion (Fig. 1D). All together, these results demonstrate that
FABP3 mRNA is a direct target of miR-1.
MiR-1 regulates secreted levels of FABP3 in vitro and in vivo.
Since FABP3 is a fatty acid (FA) binding protein involved
in the cellular uptake of FAs, we used an enzyme-linked
immunosorbent assay (ELISA) to assess whether miR-1
expression might be inversely correlated with the extracel-
lular FABP3 protein level. First, we determined the FABP3
protein level in C2C12 muscle cells, a myogenic cell line in
which we recently demonstrated up-regulation of endoge-
nous miR-1 expression upon the switch from proliferation
to differentiation (3). As expected, the levels of cytosolic
(cFABP3) and secreted FABP3 (sFABP3) were signifi-
cantly decreased when C2C12 cells were switched from
growth to differentiation medium (Fig. 2A), whereas trans-
fection of cells with a miR-1 inhibitor was sufficient to
prevent with this reduction (Fig. 2A). Similar findings were
obtained in neonatal CMs, in which overexpression or
reduction of miR-1 was sufficient to induce an inverse
modulation of both intra- and extracellular levels of FABP3
(Fig. 2B). Consistent with our previous studies demonstrat-
Abbreviations
and Acronyms
ACRO  acromegaly
AS  aortic valve stenosis
cFABP3  cytosolic fatty
acid-binding protein-3
CM  cardiomyocyte
dox  doxycycline
ELISA  enzyme-linked
immunosorbent assay
FA  fatty acid
FABP3  fatty acid-binding
protein-3
GH  growth hormone
GHD  growth hormone
deficiency
HF  heart failure
IGF  insulin-like growth
factor
MiR  microRNA
sFABP3  secreted fatty
acid-binding protein-3
TAC  transaortic
constriction
TAVI  transcatheter aortic
valve implantation
Tg  transgenic
UTR  untranslated regioning a role of the IGF-1 pathway in negatively regulating
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sFABP3 protein levels were found to be up-regulated in
response to IGF-1 exposure (Fig. 2B).
Finally, to further confirm whether miR-1 plays a direct
role in controlling the secreted levels of FABP3 in vivo, we
used a gain-of-function approach by generating a transgenic
(Tg) mouse model engineered for an inducible and cardiac-
specific expression of miR-1. Induction of miR-1 expression
was obtained by feeding Tg mice with food supplemented
with doxycycline (dox). As shown in Figure 2C (left), dox
administration to Tg mice resulted in a time-dependent
increase in myocardial miR-1 expression and a correspon-
dent significant reduction in sFABP3 levels in Tg compared
with control mice (Fig. 2C, right). No apparent effect of dox
administration to control mice was observed (Fig. 2C,
Online Fig. 3). The Tg mouse line, where the expression of
the miR is fine-tuned through the dose and time of dox
administration, could represent a valuable tool for miR-1
target identification, and its detailed characterization will be
published elsewhere. For the purpose of the current study,
the obtained results confirmed an inverse relationship be-
tween miR-1 and FABP3 expression, and suggest the
presence of an IGF-1/miR-1/FABP3 signaling axis.
Inverse relationship between miR-1 expression and
FABP3 levels in pressure-overloaded mouse. We (3,10)
and others (11) have previously reported that cardiac hyper-
trophy induced by transverse aortic constriction (TAC) is
associated with decreased miR-1 expression levels and
increased levels of IGF-1 (3). On the basis of this evidence,
Figure 1 FABP3 Is a Direct Target of MiR-1
(A) Sequence alignment of mature miR-1 and the 3=-UTR of FABP3 mRNA. (B) Luc
(AdmiR1) and transfected with a luciferase reporter gene linked to wild-type (FABP
(C) Representative PCR analysis (n  3) of FABP3 mRNA co-immunoprecipitated w
homogenate (positive control); neg control  no oligo (negative control). (D) Repre
GAPDH on 293 cells infected with either an adenoviral vector expressing miR-1 (A
MiR  microRNA; MOI  multiplicity of infection; UTR  untranslated region.we hypothesized that TAC might be associated with cor-responding changes in cFABP3 and sFABP3 levels. In fact,
compared with sham-operated mice, animals subjected to
TAC had increased levels of FABP3 (Fig. 3, Online Fig. 3).
Moreover, to assess whether counteracting pressure-
overload–induced miR-1 down-regulation has an effect on
the level of sFABP3, we subjected miR-1 Tg mice to TAC
and found decreased sFABP3 levels compared with wild-
type mice (Fig. 3, Online Fig. 3).
All together, these results confirm the inverse relationship
between miR-1 and FABP3 in a mouse model of cardiac
pathology.
Fasting inversely modulates miR-1 expression and
sFABP3 level in mice. Reduction of circulating IGF-1
and elevation of FAs released from the breakdown of
triglycerides are 2 events occurring in the adaptive metabolic
phase during fasting conditions (12). Therefore, if the
inverse relationship between miR-1 and FABP-3 holds true
in different pathophysiological conditions, we hypothesized
that dietary restriction might induce changes in miR-1
expression that could eventually affect the sFABP3 level. To
assess this, we measured cFABP3 levels and ventricular
miR-1 expression in wild-type mice subjected to 48 h of
fasting. As shown in Figures 4A and 4B, we found signif-
icant decreased sFABP3 levels and increased miR-1 expres-
sion levels in fasted mice. By contrast, fasting of miR-1 Tg
mice caused no additional increase in the already elevated
miR-1 expression level and consequently no further decrease
in sFABP3 level, which was already low (Figs. 4A and 4B,
activity in 293 cells infected with an adenoviral vector expressing miR-1
utated (FABP3 mut) FABP3 mRNA 3=-UTR (n  4). *p  0.05, **p  0.01.
tinylated-miR-1 in left ventricular homogenate. Input  pre-immunoprecipitation
tive Western blot and densitometric analysis (n  4 per group) for FABP3 and
) or an empty vector (control) (MOI 10). FABP3  fatty acid-binding protein-3;iferase
3) or m
ith bio
senta
dmiR1Online Fig. 4).
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FABP3 is directly regulated by the IGF-1/miR-1 regulatory
pathway, fasted wild-type mice were injected with IGF-1 in
order to re-establish its levels and, consequently, repress
miR-1 expression. As shown in Figures 4C and 4D,
injection of IGF-1, not only reduced miR-1 levels in fasted
mice to those found in fed mice, but also increased the levels
of circulating FABP3.
Thus, down-modulation of the IGF-1 pathway in vivo,
Figure 2 Inverse Relationship Between MiR-1 and FABP3
Enzyme-linked immunosorbent assay (ELISA) assay for levels of cellular and
secreted FABP3 in (A) C2C12 cells, (B) neonatal mouse cardiomyocytes
(CMs), and (C) heart lysate and plasma from control (CTL) and inducible,
cardiac-specific miR-1 transgenic (Tg) mice. CTL and Tg mice were subjected to
doxycycline (dox) administration. MiR-1 expression levels were determined by
quantitative PCR (qPCR). *p  0.05. cFABP3  cytoplasmic FABP3; DM  dif-
ferentiating medium; GM  growth medium; IGF  insulin-like growth factor;
sFABP3  secreted FABP3; other abbreviations as in Figure 1.which occurs physiologically during dietary restriction, re-sults in an up-regulation of miR-1 expression leading to a
decrease in circulating levels of FABP3.
The circulating level of sFABP3 inversely reflects myocardial
miR-1 expression in patients with aortic valve stenosis. To
address whether the aforementioned inverse relationship
between miR-1 and sFABP3 levels is significant also in the
clinical setting, we next determined miR-1 expression and
sFABP3 levels in heart biopsies and plasma from patients
with left ventricular hypertrophy due to aortic valve stenosis
(AS). In agreement with results from the TAC pressure
overload model (Fig. 3, Online Fig. 3), myocardial miR-1
expression was decreased whereas the circulating sFABP3
level was increased in AS patients compared with healthy
subjects (Fig. 5A, Online Table 1). We also compared
sFABP3 in AS patients before and after transcatheter aortic
valve implantation (TAVI) and found, as expected, that
after the significant decrease of myocardial wall stress after
TAVI (Fig. 5B, Online Table 1), the level of sFABP3
decreased also to a value comparable to that of control
individuals (Fig. 5A, Online Table 1). Along this line, the
increased level of circulating IGF-1 in pre-TAVI AS patients
was significantly blunted by the procedure (Fig. 5C).
Despite the limitation of a small patient cohort, these
results strengthen the hypothesis of a clinically significant
relationship between the IGF-1/miR-1 pathway and circu-
lating FABP3 levels, and serve as a proof of concept that the
measurements of a specific secreted miR target can be used
as an indirect biomarker of the cardiac miR level.
Figure 3
Inverse Relationship Correlation
Between miR-1 and FABP3 In Vivo
During Pathological Cardiac Hypertrophy in Mice
FABP3 levels and myocardial miR-1 expression in a mouse pressure-overload
model of pathological cardiac hypertrophy. Control and Tg mice were subjected
to doxycycline (dox) administration. (n  8). ***p  0.001. Abbreviations as
in Figures 1 and 2.
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deficiency. Growth hormone (GH) plays an important role in
the maintenance of normal cardiac function and structure
(13). Its effect on myocardial tissue is mediated by the
autocrine/paracrine action of IGF-1, which upon secretion
from the anterior pituitary gland contributes to myocardial
tissue growth, anabolic effects, increased lipolysis, and pro-
tein synthesis (14), as well as modulation of miR-1 expres-
sion (3). Perturbation of the IGF-1 axis is associated with
several cardiovascular pathologies (15), including acromeg-
aly (ACRO), a condition in which excessive GH secretion
results in elevated levels of circulating IGF-1 (16). Conges-
tive HF associated with high levels of IGF-1 is a common
complication in ACRO patients (17,18).
We have previously demonstrated that in ACRO pa-
tients, cardiac hypertrophy and increased levels of circulat-
ing IGF-1 are inversely correlated with myocardial miR-1
expression (3). We therefore hypothesized that, as a general
mechanism, the level of sFABP3 may also be increased in
ACRO patients. ELISA revealed that sFABP3 was in fact
increased in the plasma of ACRO patients, and moreover,
that medical treatment of ACRO patients, which usually
results in normalization of circulating IGF-1, was accom-
panied by down-regulation of sFABP3 to levels comparable
to those of healthy individuals (Fig. 6A, Table 1).
To further strengthen the relationship between IGF-1
and FABP3 levels in human pathologies, we analyzed
patients with growth hormone deficiency (GHD), a condi-
tion opposite to acromegaly in many aspects (19). As a
Figure 4 Fasting Modulates MiR-1 Expression and sFABP3 Lev
ELISA (A and C) and qPCR (B and D) analyses for sFABP3 and miR-1, respectively
injected with IGF-1 or phosphate-buffered saline, and either fed or fasted for 48 hmatter of fact, in GHD, the body does not produce enoughGH, a situation eventually leading to ventricular dysfunc-
tion and abnormalities in heart structure and function, such
as low cardiac output and reduced left ventricular mass. In
addition, GHD is often associated with various cardiovas-
cular risk factors, including an abnormal lipid profile and
insulin resistance, which may contribute to increased ath-
erosclerotic risk. GHD patients have lower IGF-1 plasma
levels compared with healthy subjects, and correspondingly,
we found decreased levels of sFABP3 in GHD patients
(Fig. 6B, Table 1). Furthermore, treatment of these pa-
tients, which results in an increased IGF-1 serum level, was
accompanied by a significant rise in sFABP3 (Fig. 6B,
Table 1). Finally, a linear relationship between sFABP3
levels and left ventricular mass index was found in both
ACRO and GHD patients (Fig. 6C).
Discussion
Accumulating evidence from studies on mouse models of
cardiomyopathy and human heart pathology suggest that
miR-1 is an important regulator of cardiac development and
function, and is closely associated with HF progression
(20). In particular, alterations in miR-1 levels have been
associated with the control of CM hypertrophy, cell cycle
and development, membrane excitability, and apoptosis
(3,21–23). We report here that miR-1 plays a role in
regulating the cardiac secretome. More specifically, we
demonstrate that FABP3 is a direct target of miR-1 and
that the circulating level of FABP3 is inversely related to
Mice
wing 2 weeks of induction with doxycycline, transgenic miR-1 mice were
). *p  0.05. wt  wild-type mice; other abbreviations as in Figures 1 and 2.els in
. Follo
(n  6the CM expression of miR-1.
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family of FA-binding proteins. Among the members of this
family, FABP3 is the most abundantly expressed in the
heart, where it accounts for 4% to 5% of total cellular
proteins. Its main role is to mediate the intracellular uptake
of FAs and their subsequent transport toward the mito-
chondrial -oxidation system (5). FAs account for70% of
the energy source in a healthy heart, but a number of
myocardial pathologies, such as cardiac hypertrophy, dilated
cardiomyopathy, myocardial infarction, and HF, are asso-
ciated with perturbations of energy metabolism and a shift
in substrate utilization toward either more FA or more
glucose. Albeit the role of sFABP3 in the pathophysiology
of HF is still a matter of debate and beyond the scope of this
Figure 5
Inverse Relationship Between
miR-1 and FABP3 In Vivo During
Pathological Cardiac Hypertrophy in Patients
(A) Plasma and biopsies from patients with pressure overload left ventricular
hypertrophy due to aortic valve stenosis before and after TAVI (n  5). (B) Left
ventricular (LV) wall stress and (C) IGF-1 levels in patients with pressure over-
load left ventricular hypertrophy due to aortic valve stenosis before and after
transcatheter aortic valve implantation (n  5). *p  0.05, **p  0.01,
***p  0.005. n.a.  not available; TAVI  transcatheter aortic valve implan-
tation; other abbreviations as in Figures 1 and 2.study, we here provide evidence for a previously unknowninverse relationship between cellular levels of a miR-1 and
the circulating level of its target FABP3, suggesting the
potential use of FABP3 as an indirect biomarker that mirror
the myocardial activity of miR-1 (Fig. 7).
The relationship between miR-1 and FABP3 is tightly
controlled by the IGF-1 axis. In response to ventricular
pressure overload (TAC in mice or AS in patients), the
myocardium switch to a high metabolic energy demand
follows the hypertrophic response of the myocardium. This
is paralleled by an increase in the level of IGF-1 (3,24) and a
down-regulation of miR-1 expression (10) (Figs. 5A and 5C).
As shown in this study, the reduction in miR-1 relieves its
negative regulatory control over FABP3 protein synthesis,
leading to a prompt release of the protein into the blood-
stream (Figs. 3 and 5). Accordingly, exposure of primary
CMs to IGF-1 leads to a release of high amounts of FABP3
into the extracellular medium, which can be prevented by
overexpression of miR-1 (Fig. 2B).
By contrast, fasting is associated with alterations in
circulating molecules, such as a decrease in IGF-1 and an
elevation of circulating FAs released through the breakdown
of triglycerides (12). In addition, a reduction in serum
IGF-1 has been suggested to play a role in metabolic
adaptation during malnutrition (25). Although further stud-
Figure 6 Circulating Levels of FABP3 in ACRO and GHD
ELISA for sFABP3 performed on plasma samples from patients with (A) acro-
megaly and (B) growth hormone deficiency before and after treatment.
(C) Pearson product-moment correlation between left ventricular (LV) mass
index and levels of sFABP3 measured in patients with acromegaly and growth
hormone deficiency (p  0.0001, r  0.7226). A scatterplot with regression
line is shown. Samples from healthy donors were used as control. *p  0.05.
ACRO  acromegaly; GHD  growth hormone deficiency; treat.  treatment;
other abbreviations as in Figures 1 and 2.
ical-con
growth
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relevance of circulating FABP3 activity, we found that the
molecular events that are activated under fasting lead to
increased miR-1 expression that in turn results in a de-
creased circulating level of FABP3. Consistent with our
previous report in which we demonstrated that miR-1 is
negatively regulated by the IGF-1 pathway (3), administra-
tion of IGF-1 to fasted mice was sufficient to induce
down-regulation of miR-1 and, consequently, to increase
the level of circulating FABP3 (26,27).
Of interest is the positive relationship between circulating
FABP3 and levels of IGF-1 in ACRO and GHD patients.
These are pathological conditions in which either hyper- or
hyposecretion of GH and IGF-1 lead to an increase in
cardiovascular, cerebrovascular, and metabolic morbidity.
Furthermore, despite the limitations that a replacement
Clinical and Echocardiographic Characteristics of ACRO and GHD PTable 1 Clinical and Echocardiographic Characteristics of ACR
Control
(n  18)
Pre-Treatment
(n  20)Variable
Female/male 12/16 13/7
Age, yrs 39.6 10.8 48 17.4
LV ejection fraction, % 66.2 1.2 56.2 1.0†
LV mass index, g/m 86.3 2.7 132.1 3.7†
IGF-1, ng/ml 248.65 20.1 800.3 80.9†
FABP3, ng/ml 6.8 1.5 17.8 2.5†
Values are n/n or mean  SD. *p  0.05 post-treatment versus pre-treatment for each patholog
ACRO  acromegaly; Control  healthy subjects; FABP3  fatty acid-binding protein-3; GHD 
Figure 7 Working Model of sFABP3 as an Indirect Biomarker, R
Abbreviations as in Figures 1 and 2.therapy might have in regard to over- or undertreatment, we
found that alterations in circulating levels of IGF-1 as a result
of medical interventions in these patients lead to a correspond-
ing variation in circulating FABP3 concentration.
Recently, several lines of evidence have supported the
clinical relevance of FABP3 as a biomarker for myocardial
injury (26,27). In agreement with this, our analysis of an in
vivo mouse model of cardiac damage revealed release of
FABP3 in response to injury, which was inversely related to
the cellular levels of miR-1 (Fig. 3). Interestingly, an inverse
relationship was also found in patients with different cardiac
pathological conditions (Figs. 5A and 6).
In conclusion, we report here a novel role of the muscle-
specific miR-1 in modulating the cellular and secreted levels
of FABP3 and demonstrate its potential use as an indirect
biomarker in the plasma, reflecting the cellular activity of
tsGHD Patients
Study Group
RO GHD
Post-Treatment
(n  20)
Pre-Treatment
(n  10)
Post-Treatment
(n  10)
13/7 3/7 3/7
48 17.4 62 17.5 62 17.5
63.7 1.5* 58.2 1.2† 62.7 1.6*
118.9 4.5* 98.5 3.0† 122.6 6.3*
292.1 33.2* 59.7 15.3† 105.7 22.3*
9.2 2.2* 5.23 0.5† 10.9 2.5*
dition; †p  0.05 compared with control.
hormone deficiency; IGF  insulin-like growth factor; LV  left ventricular.
ting the Cellular Activity of MiR-1atienO and
ACeflec
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
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measuring the cellular miR-1 levels in humans (Fig. 7).
Study limitations. Despite the relevance of our finding, a
limitation of the study is that the pathophysiological rele-
vance of variations in circulating FABP3 remains unsolved.
In fact, it is still a matter of debate: 1) whether and how
FABP3 may affect cardiac metabolism during remodeling
stress; 2) whether changes in circulating FABP3 may
discriminate between different types of remodeling (concen-
tric, eccentric, with/without left ventricular dysfunction);
and 3) whether it may confer any prognostic information.
Answering these questions will require further additional
studies.
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